Imbria Pharmaceuticals is a technology company.
Imbria Pharmaceuticals has raised $59.0M across 1 funding round.
Imbria Pharmaceuticals has raised $59.0M in total across 1 funding round.
Imbria Pharmaceuticals is a clinical-stage biotechnology company developing ninerafaxstat, a first-in-class therapy targeting cardiac energy metabolism to treat cardiovascular diseases like non-obstructive hypertrophic cardiomyopathy (nHCM) and heart failure with preserved ejection fraction (HFpEF).[1][2][3][6] It serves patients with serious cardiovascular disorders where current treatments are limited, addressing the core problem of impaired cardiac energy production and efficiency without negatively impacting heart rate, rhythm, ejection fraction, or blood pressure.[1][3][6] Based in Boston, MA, the company is advancing a Phase 2b FORTITUDE-HCM trial (readout expected 2026) and has raised significant funding, including a $57.5M Series B, backed by top investors like RA Capital and SV Health Investors.[2][5][6]
Recent momentum includes positive Phase 2 results from IMPROVE-HCM (presented at ACC.24) and IMPROVE-ISCHEMIA (presented at ESC Congress 2024), leadership appointments like CEO Alvin Shih, MD, and CMO Albert M. Kim, MD, PhD, plus a partnership with the Hypertrophic Cardiomyopathy Association.[5][6]
Founded in 2018 by doctors focused on patient needs, Imbria emerged from insights into cardiac energy metabolism as a fundamental driver of cardiovascular disease.[3][5] The idea stemmed from recognizing energetic impairments in conditions like nHCM and HFpEF, leading to the development of ninerafaxstat as a "pipeline-in-a-pill" with broad utility.[1][3] Early traction includes positive Phase 2 trial results and a strong funding syndicate, enabling clinical advancement.[2][6]
Imbria rides the trend of precision cardiology, shifting from symptom management to metabolic therapies amid rising cardiovascular disease burdens from aging populations and metabolic syndromes.[3][6] Timing aligns with unmet needs in nHCM and HFpEF, where few effective options exist, fueled by market forces like advancing trial readouts (e.g., FORTITUDE-HCM in 2026) and investor interest in cardio-metabolic biotech.[2][5] It influences the ecosystem by pioneering energy-focused approaches, potentially expanding to other cardiometabolic disorders and attracting partnerships.[1][5]
Imbria's path hinges on 2026 Phase 2b FORTITUDE-HCM readout, which could validate ninerafaxstat and propel Phase 3 trials or partnerships.[2][6] Trends like AI-driven drug discovery and cardio-metabolic convergence will shape growth, with potential influence expanding if it disrupts stagnant cardiovascular treatment paradigms. As a Boston biotech leader targeting energy deficits, Imbria positions to transform care for millions, building on its clinician-founded roots and clinical momentum.[3][5][6]
Imbria Pharmaceuticals has raised $59.0M in total across 1 funding round.
Imbria Pharmaceuticals's investors include Forbion, RA Capital.
Imbria Pharmaceuticals has raised $59.0M across 1 funding round. Most recently, it raised $59.0M Series B in April 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2025 | $59.0M Series B | Forbion, RA Capital |